Test Price
2,800 AED✅ Home Collection Available
AMPD2 Gene Sequencing for Pontocerebellar Hypoplasia Type 9 in UAE | 2,800 AED | DNA Labs UAE
Executive Summary & Core Metrics
Clinical Certainty, Delivered
- Accuracy Guarantee: 99.9% diagnostic sensitivity achieved through ISO 9001:2015-certified NGS workflows (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection, available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic post-test consultation with a genetic counsellor to interpret results and plan follow-up.
- Insurance: Direct billing verification through WhatsApp at +971 54 548 8731.
Clinical Context & Diagnostic Value
This targeted gene sequencing assay identifies pathogenic variants in AMPD2 responsible for pontocerebellar hypoplasia type 9, a severe autosomal recessive neurodevelopmental disorder. The test provides comprehensive coverage of all coding exons and flanking intronic regions, enabling definitive molecular diagnosis and accurate carrier risk assessment for at-risk family members.
Test Overview & Methodology
AMPD2 gene sequencing employs next-generation sequencing (NGS) technology to interrogate the complete coding sequence and splice-site junctions of the AMPD2 gene. The analysis detects single nucleotide variants, small insertions and deletions, and can infer copy number alterations from depth-of-coverage data. All clinically significant findings are confirmed by orthogonal Sanger sequencing prior to report release.
| Parameter | Our AMPD2 NGS Test | Closest Alternative (Sanger Single-Site) |
|---|---|---|
| Precision | Full gene sequencing with copy number variant detection, >99.9% analytical sensitivity | Only targets previously known familial variant; misses novel or deep intronic mutations |
| Method | Next Generation Sequencing (NGS) with Sanger validation | Sanger sequencing of one specific region |
| Speed | 3 to 4 weeks | 6–8 weeks |
Physician Insight & Safety Protocols
“Interpreting AMPD2 sequencing results requires integration with the complete clinical phenotype. A negative result does not rule out pontocerebellar hypoplasia; correlation with neuroimaging findings and detailed neurological examination remains essential. Pre-test genetic counselling should address the scope of analysis, the possibility of variants of uncertain significance, and implications for family members.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Medication Advisory
Patients and caregivers must not discontinue or modify any prescribed treatments without explicit consultation with the managing physician. This genetic test provides diagnostic information; all therapeutic decisions require comprehensive clinical evaluation and should not be based solely on molecular findings.
Safety Exclusion Criteria & Emergency Red Flags
- Inability to safely collect a blood sample due to severe bleeding disorder or extreme venous access difficulty – alternative DNA extraction from buccal swab may be considered after specialist approval and in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Patients under 18 years require informed consent from a legal guardian, aligned with UAE personal data protection standards under Federal Decree-Law No. 45 of 2021 and Federal Law No. 2 of 2019.
- If the patient experiences acute neurological deterioration including new-onset seizures, loss of consciousness, severe dysphagia with aspiration risk, or sudden worsening of motor function, proceed immediately to the nearest emergency department—do not delay for test scheduling.
Patient FAQ & Clinical Guidance
1. What is AMPD2 gene testing and why is it recommended?
AMPD2 gene sequencing detects disease-causing variants in the AMPD2 gene that cause pontocerebellar hypoplasia type 9, a severe inherited neurological condition. This test is recommended for children presenting with global developmental delay, progressive microcephaly, and characteristic MRI findings, as well as for carrier testing in at-risk families.
2. How is the sample collected and when will I receive the results?
A certified phlebotomist collects a small blood sample during a home visit using cold-chain transport, and results are typically ready in 3 to 4 weeks. The sample is processed in our ISO-accredited laboratory using NGS, and the report includes a clinically interpreted summary suitable for your specialist.
3. Is this genetic test covered by my health insurance in the UAE?
We provide immediate insurance eligibility verification through WhatsApp; many UAE policies cover advanced genetic testing when medically justified by a neurologist or clinical geneticist. Contact us at +971 54 548 8731 with your policy details, and our billing team will confirm coverage within one business day.
4. What happens after the results are ready?
A genetic counsellor will contact you to schedule a telephonic consultation, explain the findings, and discuss recommended next steps. A written clinical report is provided for your referring physician, and the laboratory offers ongoing support for family cascade testing if a pathogenic variant is identified.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
All procedures at DNA Labs UAE strictly comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for the collection, processing, and storage of patient genetic information. Clinical safety and patient consent requirements are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Health data handling and confidentiality in diagnostic workflows adhere to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Our DHA-licensed facility operates under the regulatory oversight of the Dubai Health Authority.
Clinical & Logistical Metadata
| Test Name | AMPD2 Gene Sequencing for Pontocerebellar Hypoplasia Type 9 |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood (3–5 mL in EDTA tube) |
| Methodology Used | Next Generation Sequencing (NGS) with Sanger confirmation |
| ICD-10-CM Code | G31.89 |
| LOINC Code | 55233-1 |
| DHA Facility License & Laboratory Address | DHA Facility License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians